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ABSTRACT 
A simple isocratic RP-HPLC stability indicating method has been developed and subsequently 
validated for the determination of Irinotecan HCl and its related substance (SN-38) in 
pharmaceutical dosage forms as per ICH guidelines. The separation achieved on a reversed phase 
Phenomenex Luna C18 Column, 5µ, 250 × 4.60 mm as a stationary phase and 0.5% trichloro 
acetic acid: Acetonitrile: Methanol (60: 20: 20 v/v/v) as mobile phase at a flow rate of 1.0 
mL/min. The UV detection was performed at 372 nm.  The retention time (Rt) for Irinotecan HCl 
and SN-38 was found to be 8.65 and 7.30 min respectively. The detector response was linear in 
the concentration range of 30-150 µg/mL. The respective linear regression equation being Y= 
5233.x + 13299 with R2   0.999. The percentage of Irinotecan HCl in pharmaceutical dosage 
form was found to be 100.5% and the percentage of related substance (SN-38) in formulation 
was found to be 0.19%. The limit of detection of Irinotecan was 0.014 µg/mL and the limit of 
quantification was 0.045 µg/mL. The results of the study showed that, the proposed RP-HPLC 
method was simple, rapid, precise, accurate and stability indicated, which can be used for the 
routine determination of Irinotecan HCl and its related substance (SN-38) in pharmaceutical 
dosage form. 
 
KEY WORDS:        Irinotecan HCl, SN-38, RP-HPLC, Related substance. 
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Chapter 1 
INTRODUCTION (1-24) 
IMPURITY STUDIES (1-15) 
mpurities in a drug substance (a new chemical entity of therapeutic interest) or drug product 
(a drug substance formulated into a suitable product for administration to patient) may 
cause serious side effects and hence we need to isolate and characterize impurities. 
The following definition of impurity is currently under consideration by the regulatory bodies, 
which is likely to be included in the future guidance: 
Impurity: any entity of the drug substance (bulk material) or drug product (final container 
product) that is not the chemical entity defined as the drug substance, an excipient, or other 
additives to the drug product. 
Related substances: These substances are structurally related to the drug substance and may be 
identified or unidentified degradation products or impurities arising from a manufacturing 
process or during storage of a material.  
Impurity profile has become essential as per various regulatory requirements. Various regulatory 
authorities like ICH, USFDA, Canadian Drug and Health Agency are emphasizing on the purity 
requirements and the identification of impurities in Active Pharmaceutical Ingredient’s (API’s). 
Qualification of the impurities is the process of acquiring and evaluating data that establishes 
biological safety of an individual impurity; thus, revealing the need and scope of impurity 
profiling of drugs in pharmaceutical research The International Conference on Harmonization of 
Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) has also 
published guidelines for validation of methods for analyzing impurities in new drug substances, 
products, residual solvents and microbiological impurities.[2-5] 
 
As per ICH guidelines Impurities are listed alphabetically as given below. 
• By-product  
• Degradation product 
I
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• Interaction product 
• Intermediate  
• Penultimate intermediate 
• Related product 
• Transformation product 
By-products: The unplanned compounds generated in the reaction to produce API are generally 
called by-products. For example during the synthesis of paracetamol we get diacetylated 
paracetamol which is the unexpected product called by-product. 
Degradation products: The compounds produced as a result of decomposition of the material of 
interest or API is often called degradation products. Due to degradation, impurities may also be 
formed. Degradation of beta lactum ring in penicillin and cephalosporin are the examples of 
degradation products. 2-(4-formylphenyl) propionic acid, 2-(4-methylphenyl) propionic acid , 2-
(4-ethylphenyl) propionic acid , 4- isobutylacetophenone , 2-(4-n-propylphenyl) propionic acid 
and 2-(4-n-butylphenyl) propionic acid are the reported degradation products of ibuprofen. 
Interaction products: This term is slightly more inclusive and more difficult to evaluate than the 
two previously described, i.e., by-products and degradation products, in that it takes into account 
interactions that could possibly occur between various involved chemicals – purposely or 
inadvertently. 
Intermediates: The planned compounds produced during synthesis of the desired substance are 
called intermediates, especially if they have been isolated and characterized. 
Penultimate intermediate: As the name implies, this is the last compound in the synthetic chain 
just preceding the production of the ultimate desired compound. 
Related products: As suggested previously, the term “related products” tends to imply that the 
impurity is similar to the drug substance, and it thus tends to downplay the negativity frequently 
attached to the term “Impurity”.  
Transformation products: This is relatively a term that relates to theorized and non-theorized 
products that may be produced in the reaction. 
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1.1.Classification of impurities 
According to ICH guidelines, impurities can be broadly classified in to three categories for the 
drug substance produced by chemical synthesis: 
• Organic impurities (starting materials, process-related products, inter- mediators, and 
degradation products). 
• Inorganic impurities (salts, catalysts, ligands, and heavy metals or other residual metals). 
• Residual solvents (organic and inorganic liquids used during production and/or 
recrystallization). 
 
1.2. Need to Isolate and Characterize Impurities 
Impurities are generally assumed to be inferior to API because they might not have the same 
level of pharmacologic activity. However, they are not necessarily always inferior. From the 
standpoint of its usage, the drug substance is compromised in terms of purity even if it contains 
another material with superior pharmacologic or toxicologic properties. At first pass this may not 
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be readily apparent; however, on further thought it will become clear that if we are to ensure that 
the accurate amount of the drug substance is being administered to the patient, we must assess its 
purity independent of the extraneous materials. Therefore, any extraneous material present in the 
drug substance or active ingredient must be considered an impurity even if it is totally inert or 
has superior pharmacologic properties, so that an appropriate evaluation of its content in the drug 
product can be made. The control of low-level impurities is of great importance when a drug is 
taken in large quantities. Impurities can also affect the purity of API or can be harmful to 
patients. 
1.2. Sources of Impurities 
Impurities can originate from various sources, the most obvious source of impurities is from 
synthesis of API, where intermediates and by-products may be carried into the API as impurities 
or become a source of other impurities resulting from them. Following are the sources of the 
impurities 
1.3.1. Crystallization- related impurities 
Polymorphism is the term used to denote crystal systems where a substance can exist in different 
crystal packing arrangements, all of which have the same elemental composition. It is also 
possible to have crystal systems where the substance exists in different crystal packing 
arrangements, each of which has a different elemental composition; this phenomenon is known 
as solvatomorphism. The nature of the crystal structure of a given material can influence the 
following properties: 
• Conductivity 
• Crystal hardness 
• Crystal shape and color 
• Density 
• Diffusivity 
• Dissolution rate 
• Electrolytic conductivity 
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• Enthalpy of transitions 
• Heat capacity 
• Heat of solution 
• Hygroscopicity 
• Latent heat of fusion 
• Melting or sublimation properties 
• Phase diagrams 
• Rates of reactions 
• Refractive index 
• Solubility 
• Surface tension 
• Viscosity 
• Volume 
1.3.2. Stereochemistry-related impurities 
Substances having similar chemical structure but having different spatial orientation are 
considered as stereo-chemical impurities in the API. Stereoisomerism is possible in molecules 
that have any of the following characteristics: 
• One or more center of chirality 
• Helicity (e.g., helical nature of tertiary structure of proteins, polysaccharides and 
nucleotides) 
• Planar chirality(e.g., polycyclophanes) 
• Axial chirality (e.g,.spiranes with cyclic skeleton ) 
• Torsional chirality (e.g., torsion about double or single bonds like cis and trans isomers 
and rotomers) 
• Topological asymmetry (e.g., catenanes). 
Pthalidomide tragedy is the good example for stereo-chemical impurities.  
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1.3.3 Residual solvents 
Water is commonly present in drug products. As a result, water is by far the most commonly 
found volatile impurity in drug products, and most of the time it is not even considered an 
impurity. A number of solvents that are used for the synthesis of the API or formulation of the 
drug product can be present in the drug product. The content of these solvents, which are 
commonly called organic volatile impurities (OVI), is generally determined by the OVI methods 
specified in the compendia. 
1.3.4. Synthetic intermediates and by-products 
In addition to the residual solvents, polymorphic, solvatomorphic, and chiral impurities 
mentioned previously, impurities in a pharmaceutical compound or a new chemical entity (NCE) 
can originate during the synthetic process from raw materials, intermediates, and/or by-products. 
The solvents used in synthesis are also likely to involve a number of impurities that may extend 
from trace levels to critical quantities that can react with various chemicals used in the synthesis, 
to give rise to other impurities. 
1.3.5. Formulation-related impurities 
As mentioned before, many impurities in a drug product can originate from excipient used to 
formulate a drug substance. In addition, a drug substance is subjected to a variety of conditions 
in the process of formulation that can cause its degradation or have other undesirable reactions. 
For example if heat is used for drying purpose or for some other reason, it can hasten 
degradation. 
1.3.6. Impurities arising during storage 
A number of impurities can originate during storage (shelf life) or shipment of drug products. It 
is essential to carry out stability studies to predict, evaluate, and ensure drug product safety. 
Stability, however, can have different meanings to different people, based on their discipline in 
the pharmaceutical sciences and industry. 
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1.3.7. Method related impurity 
Terminal sterilization by autoclave for the diclofenac injectables known to produse impurity of 
1-(2, 6-dichlorophenyl) indolin-2-one. Intramolecular cyclic reaction of diclofenac sodium cause 
the formation of indolinone impurity during autoclave method. 
1.3.8. Mutual interaction amongst ingredients 
 In multi component dosage forms there may be a chance to get mutual interaction, 
particularly this occurs in multivitamin dosage forms. the presence of nicotinamide in a 
formulation containing four vitamins (nicotinamide, pyridoxine, riboflavin, and thiamine) can 
cause the degradation of thiamine to a sub-standard level within a one year shelf life of vitamin 
B-complex injections.  
1.3.9 Functional group related degradations 
API containing ester groups can readily be hydrolysed causing the formation of degraded 
products. For Eg aspirin, benzocaine, benzylpenicillin, oxazepam and lincomycin,cefotaxime, 
ethyl paraben, and cefpodoxime undergo hydrolysis readily causing the degradation of API. 
 
API containing hydroxyl group directly bonded to an aromatic ring (viz phenol derivatives such 
as catecholamines and morphine), conjugated dienes (viz vitamin A and unsaturated free fatty 
acids), heterocyclic aromatic rings, nitroso and nitrite derivatives, and aldehydes (especially 
flavorings) are all susceptible to oxidative degradation. 
 
Some of the API undergoes degradation on exposure to light. API like Ergometrine [27], 
nifedipine [28], nitroprusside, riboflavin and phenothiazines are veryliable to photo-oxidation. 
 
1.4. ANALYTICAL METHOD DEVELOPMENT 
Analytical method development for the quantification of low-level impurities present in 
pharmaceuticals can be thought of as a three-step process: 
1. Sample set selection for analytical method development 
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2. Screening of chromatographic conditions and phases, typically using the linear-solvent-
strength model of gradient elution 
3. Optimization of the method to fine-tune parameters related to ruggedness and robustness. 
This can be accomplished using a factorial optimization approach. 
1.5 CHARACTERISATION OF IMPURITIES 
1.5.1. SPECTROSCOPIC AND SEPARATION METHODS 
The following spectroscopic measurement techniques have been used for characterizing and 
isolating impurities; most of these are very useful as detectors for chromatographic methods: 
• Ultraviolet(UV) 
• Infrared(IR) 
• Raman spectroscopy 
• Mass spectrometry(MS) 
• Nuclear magnetic resonance(NMR)  
• Capillary electrophoresis (CE) 
• Thin-layer chromatography(TLC) 
• Gas chromatography (GC) 
• High- pressure liquid chromatography (HPLC) 
• Supercritical fluid chromatography (SFC) 
• Chiral separations 
Ultraviolet spectrophotometry (UV) at a single wavelength furnishes minimum selectivity of 
analysis; however, with the current accessibility of diode array detectors, it is conceivable to 
obtain sufficient simultaneous information at various wavelengths to assure greater reliability. 
Infrared spectrophotometry (IR) affords specific information on some functional groups that 
offer selectivity and aloe quantification. 
Raman spectroscopy is based on the measurement of scattered electromagnetic radiation 
resulting from the irradiation of matter. 
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Thin-layer chromatography coupled with densitometric detection is a highly sensitive method for 
quick assessment of the purity of various compounds including reference standards.  
Mass spectrometry (MS) provides excellent structural information, and, based on the resolution 
of the instrument, it may be an effective tool for differentiating molecules with small differences 
in molecular weight. However, it has finite uses as a quantitative procedure. 
Nuclear magnetic resonance spectroscopy (NMR) provides reasonably detailed structural 
information on a molecule and is an extremely useful method for characterization of impurities; 
however, its use as a quantitative method is limited. 
Capillary electrophoresis is an effective technique in situations where very low quantities of 
samples are available and high resolution is essential. 
Gas chromatography is an extremely useful technique for quantification. It can afford the desired 
resolution, selectivity and ease of quantification. 
High-pressure liquid chromatography is often referred to as high-performance liquid 
chromatography today. Both terms can be abbreviated as HPLC, and the terms are used 
interchangeably by chromatographers. The applications of this very effective technique have 
been significantly expanded for the pharmaceutical chemist by the use of a variety of detectors 
such as fluorescence, electrometric, MS and so forth. 
Supercritical fluid chromatography (SFC) offers some of the advantages of GC in terms of 
detection and of HPLC in terms of separations, in that volatility of the sample is not of 
paramount importance.  
1.6. REGULATORY GUIDANCE ON IMPURITIES 
The United States Food and Drug Administration (FDA) have endorsed the guidance prepared 
under the auspices of the International Conference on Harmonization of Technical Requirements 
for Registration of Pharmaceuticals for Human Use (ICH). 
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Fig. 1 Decision tree     for identification and qualification of impurities: 
 
 
 
   Yes      No 
 
    Yes     es                      Yes 
                  
                     No 
 
    
         Yes              No 
               
      Yes 
               
          No          No  
         No     No Yes      
             
                
             
     No        
             
             
             
             
             
   
 
 
                                  
      No                                                    Yes 
Consider patient population and duration of use and 
consider conducting:        
A.Genotoxicity studies (point mutation,                
chromosomal aberration)     
B.General toxicity studies (one species, usually 14 to 90 
days)                
C.Other specific toxicity end points, as appropriate
Any clinically 
relevant adverse 
effects?
Qualified Reduce to 
safe level 
Is impurity greater 
than identification 
threshold? 
No action 
Structure    
identified? 
       Any 
known human 
relevant risks? 
Reduce to 
safe level 
Reduce to not 
more than 
identification 
threshold? 
Reduce to 
safe level 
Greater than 
qualification 
threshold ? 
No action 
Reduce to not 
more than 
identification 
threshold?
Dept. of Pharmaceutical Analysis                                                               Introduction 
 
K. M. C. H College of Pharmacy  Page 12 
 
 
2. METHOD DEVELOPMENT (16-19) 
 
Numerous methods are required to characterize drug substances and drug products. 
Specifications may include description; identification; assay (of composite sample); tests for 
organic synthetic process impurities, inorganic impurities, degradation products, residual 
solvents, and container extractables; tests of various physicochemical properties, chiral purity, 
water content, content uniformity, and antioxidant and antimicrobial preservative content; 
microbial tests; dissolution/disintegration tests; hardness/friability tests; and tests for particle size 
and polymorphic form. Some of these tests may be precluded, or additional tests may be added 
as dictated by the chemistry of the pharmaceutical or the dosage form. Due to the variability in 
specific tests required to fully characterize a pharmaceutical, it is difficult to provide a 
comprehensive discussion to address all aspects of pharmaceutical development. However, the 
requisite tests can be broadly subdivided into three main categories: 
• Tests concerned with solid-state characterization 
• Compendial tests 
• Quantitative tests to characterize drug substance and drug product composition 
 
Quantitative tests to characterize drug substance and drug product composition require 
that significant consideration be given to method development. Methods such as thin layer 
chromatography, gas chromatography, HPLC, supercritical fluid chromatography, and capillary 
electrophoresis are used for pharmaceutical analysis. High-pressure, or high-performance, liquid 
chromatography (both are abbreviated as HPLC or simply LC; is predominantly used in the 
pharmaceutical industry for evaluations of a large variety of samples. It is the method of choice 
for checking purity of new chemical entities, monitoring changes in synthetic procedures or scale 
up, evaluating new formulations, and carrying out quality control/assurance of the final drug 
product. As mentioned before, phase-appropriate HPLC method development must be given 
serious consideration during method development. 
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2.1 HPLC METHOD DEVELOPMENT STEPS: 
The steps will be discussed in the same order as they would be investigated during the 
method development process. The rational will be illustrated by focusing on developing a 
stability-indicating HPLC-UV method for related substances (impurities). The principles, 
however, will be applicable to most other HPLC methods. 
The following is a suggested method development timeline for a typical HPLC-UV 
related substance method. The percentage of time spent on each stage is proposed to ensure the 
scientist will allocate sufficient time to different steps. In this approach, the three critical 
components for a HPLC method (sample preparation, HPLC analysis and standardization) will 
first be investigated individually. Each of these steps will be discussed in more detail in the 
following paragraphs. 
 
Step 1: Define method objectives and understand the chemistry of analytes  
Determination of the goals for method development (e.g., what is the intended use of the 
method?), and understand the chemistry of the analytes and the drug product. 
 
Step 2: HPLC Initial conditions  
Development of preliminary HPLC conditions to achieve minimally acceptable separations. 
These HPLC conditions will be used for all subsequent method development experiments. 
 
Step 3: Procedure for Sample preparation 
Develop the suitable sample preparation scheme for the drug product 
 
Step 4: Standardization  
Determination of the appropriate standardization method and the use of relative response factors 
in calculations. 
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Step 5: Final method optimization or robustness  
Identification of the “weaknesses” of the method and optimization of the method through 
experimental design and understand the method performance with different conditions, different 
instrument set ups and different samples. 
 
Step 6: Validation of method 
 The complete method validation according to ICH guidelines 
 
2.1.1. DEFINE METHOD OBJECTIVES 
There is no absolute end to the method development process. The question is what is the 
“acceptable method performance”? The acceptable method performance is determined by the 
objectives set in this step. This is one of the most important considerations often overlooked by 
scientists. In this section, the different end points (i.e., expectations) will be discussed in 
descending order of significance. 
 
2.1.1.1. Analytes: 
For a related substance method, determining the “significant and relevant” related 
substances is very critical. With limited experience with the drug product, a good way to 
determine the significant related substances is to look at the degradation products observed 
during stress testing. Significant degradation products observed during stress testing should be 
investigated in the method development. 
Based on the current ICH guidelines on specifications, the related substances method for 
active pharmaceutical ingredients (API) should focus on both the API degradation products and 
synthetic impurities, while the same method for drug products should focus only on the 
degradation products. In general practice, unless there are any special toxicology concerns, 
related substances below the limit of quantitation (LOQ) should not be reported and therefore 
should not be investigated. 
In this stage, relevant related substances should be separated into 2 groups: 
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2.1.1.2. Significant related substances: Linearity, accuracy and response factors should be 
established for the significant related substances during the method validation. To limit the 
workload during method development, usually 3 or less significant related substances should be 
selected in a method. 
 
2.1.1.3. Other related substances: These are potential degradation products that are not 
significant in amount. The developed HPLC conditions only need to provide good resolution for 
these related substances to show that they do not exist in significant levels. 
 
2.1.2. Resolution (Rs) 
A stability indicating method must resolve all significant degradation products from each other. 
Typically the minimum requirement for baseline resolution is 1.5. This limit is valid only for 2 
Gaussian-shape peaks of equal size. In actual method development, Rs = 2.0 should be used as a 
minimum to account for day to day variability, non-ideal peak shapes and differences in peak 
sizes. 
 
2.1.3. Limit of Quantitation (LOQ) 
The desired method LOQ is related to the ICH reporting limits. If the corresponding ICH 
reporting limit is 0.1%, the method LOQ should be 0.05% or less to ensure the results are 
accurate up to one decimal place. However, it is of little value to develop a method with an LOQ 
much below this level in standard practice because when the method is too sensitive, method 
precision and accuracy are compromised. 
 
2.1.4. Precision, Accuracy 
Expectations for precision and accuracy should be determined on a case by case basis. For a 
typical related substance method, the RSD of 6 replicates should be less than 10%. Accuracy 
should be within 70 % to 130% of theory at the LOQ level. 
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2.1.5. Analysis time 
A run time of about 5-10 minutes per injection is sufficient in most routine related substance 
analyses. Unless the method is intended to support a high-volume assay, shortening the run time 
further is not recommended as it may compromise the method performance in other aspects (e.g., 
specificity, precision and accuracy.) 
 
2.1.6. Adaptability for Automation 
For methods that are likely to be used in a high sample volume application, it is very important 
for the method to be “automatable”. The manual sample preparation procedure should be easy to 
perform. This will ensure the sample preparation can be automated in common sample 
preparation workstations. 
 
2.1.7. UNDERSTAND THE CHEMISTRY 
Similar to any other research project, a comprehensive literature search of the chemical and 
physical properties of the analytes (and other structurally related compounds) is essential to 
ensure the success of the project. 
 
2.1.8. Chemical Properties 
Most sample preparations involve the use of organic-aqueous and acid-base extraction 
techniques. Therefore it is very helpful to understand the solubility and pKa of the analytes. 
Solubility in different organic or aqueous solvents determines the best composition of the sample 
solvent. pKa determines the pH in which the analyte will exist as a neutral or ionic species. This 
information will facilitate an efficient sample extraction scheme and determine the optimum pH 
in mobile phase to achieve good separations. 
 
2.1.9. Potential Degradation Products 
Subjecting the API or drug product to common stress conditions provides insight into the 
stability of the analytes under different conditions. The common stress conditions include acidic 
pH, basic pH, neutral pH, different temperature and humidity conditions, oxidation, reduction 
and photo-degradation. These studies help to determine the significant related substances to be 
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used in method development, and to determine the sample solvent that gives the best sample 
solution stability. 
In addition, the structures of the analytes will indicate the potential active sites for degradation. 
Knowledge from basic organic chemistry will help to predict the reactivity of the functional 
groups. For example, some excipients are known to contain trace level of peroxide impurities. If 
the analyte is susceptible to oxidation, these peroxide impurities could possibly produce 
significant degradation products. 
 
2.1.10. Sample Matrix 
Physical (e.g., solubility) and chemical (e.g., UV activity, stability, pH effect) properties of the 
sample matrix will help to design an appropriate sample preparation scheme. For example, 
Hydroxypropyl Methylcellulose (HPMC) is known to absorb water to form a very viscous 
solution, therefore it is essential to use mostly organic solvents in sample preparation. 
 
2.2. INITIAL METHOD CONDITIONS 
The objective at this stage is to quickly develop HPLC conditions for subsequent method 
development experiments. A common mistake is that scientists spend too much time at this stage 
trying to get a perfect separation. 
 
2.2.1. Preliminary HPLC Conditions 
In order to develop preliminary HPLC conditions in a timely fashion, scientists should use 
artificial mixtures of active pharmaceutical ingredients and related substances at relatively high 
concentrations (e.g., 1-2% of related substance relative to API) to develop the preliminary HPLC 
conditions. The concentration ratio between API and the related substances should be maintained 
to ensure the chromatography represents that of a real sample. Alternatively, a highly stressed 
sample (e.g., 5% degradation) can also be used at this stage. With the known composition and 
high levels of degradation products in the sample, one can evaluate the chromatography to 
determine whether there are adequate separations for all analytes. The high concentrations of 
related substances are used to ensure all peaks will be detected. 
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Computer assisted method development can be very helpful in developing the preliminary HPLC 
conditions quickly. Since the objective at this stage is to quickly develop HPLC conditions for 
subsequent method development experiments, scientists should focus on the separation of the 
significant related substances instead of trying to achieve good resolution for all related 
substances. These significant related substances should be baseline resolved from each other 
with Rs > 2.0. After the preliminary method development, the HPLC conditions can be further 
fine-tuned at a later stage (see section 8, method optimization/ robustness) to achieve the 
required specificity for the other related substances. 
 
2.2.3. Aged HPLC Column 
An aged HPLC column should be used to develop the initial HPLC conditions. Usually it is more 
difficult to achieve the required resolution with an aged column (e.g., column with about 200 
injections). This will reflect the worst case scenario likely to be encountered in actual method 
uses, and help the long-term method robustness. 
In general, develop all methods with HPLC columns from the same vendor. The preferred brand 
of HPLC column should be selected primarily based on the long term stability and lot to lot 
reproducibility. 
 
2.4. SAMPLE PREPARATION 
2.4.1 Selection of Sample Solvent 
This stage focuses on the selection of the sample solvent (for extraction) and the proper sample 
preparation procedures. Investigate the effect of sample solvents of different % organic, pH, 
extraction volume and extraction procedure on accuracy, precision, sensitivity (LOQ) and the 
changes in the chromatography (e.g., peak shape, resolution). Whenever possible use the mobile 
phase in the sample preparation. This will ensure that there will not be any compatibility issues 
between the sample solution and the HPLC conditions. 
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2.4.1.1. Accuracy: To investigate the accuracy in sample preparation (i.e., extraction efficiency), 
prepare a spiked solution by adding known amounts of related substances into a sample matrix. 
Compare responses of the spike solutions and the neat standard solutions to assess the recovery 
from the sample preparation. In this stage, since only one particular step is being investigated 
(i.e., sample preparation), close to theoretical recovery should be observed at this point (e.g., 90-
110%). 
 
2.4.1.2. Precision: Use the stressed sample to represent the worst case scenario and perform 
replicate sample preparations from the same sample composite. Investigate the consistency of the 
related substance profile (i.e., any missing peaks?) and the repeatability results from these 
preparations. 
Another objective is to determine the sample concentration that gives an acceptable LOQ (Signal 
to Noise ratio, S/N) in low level spike concentrations. The sample concentration should be low 
enough to maintain linearity and precision, but high enough to achieve the desired LOQ. For 
example, if the ICH reporting limit for this drug product is 0.1%, the LOQ of the method should 
be less than 0.05% (i.e., desired LOQ, in %). By using spike sample solutions of very diluted 
concentrations for the significant related substances, estimate the concentrations that give a S/N 
of about 10 for the significant related substances. This estimated concentration is the 
approximate LOQ concentration (i.e., estimated LOQ concentration, in μg/mL). 
The following equation can be used to estimate the target sample concentration for the method: 
Target sample concentration = estimated LOQ concentration (μg/mL) x 1/desired LOQ (%) x 
100% 
 
2.5. STANDARDIZATION 
2.5.1. Area % method 
If the response of the active pharmaceutical ingredient is linear from LOQ to the nominal sample 
concentration, use the % area approach where the related substance is reported as % area. This is 
the most straightforward approach, and doesn’t require the preparation of standard solutions. It 
also has the highest precision since preparation to preparation variation will not affect the results. 
However, in order to ensure the concentration is linear within this range, the sample 
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concentration is usually limited and this will reduce the method sensitivity (i.e., increase LOQ). 
In general, use this approach as long as the desired LOQ can be achieved. 
2.5.2. External Standard method 
Use the external standard method if the response of the active pharmaceutical ingredient is not 
linear throughout the whole range, or the desired LOQ cannot be achieved by the area % method. 
The concentration of standard solution should be high enough to ensure the standard solution can 
be prepared accurately and precisely on a routine basis, it should be low enough to approximate 
the concentration of related substance in the sample solution. In general, the standard 
concentration should correspond to about 5 % of related substances. 
2.5.3. Wavelength Selection and Relative Response Factor 
Generate the linearity plot of API and related substances at different wavelengths. At this point, 
Photodiode Array Detector can be used to investigate the linearity of the active pharmaceutical 
ingredient and related substances in the proposed concentration range. By comparing the 
linearity slopes of the active pharmaceutical ingredient and the related substances, one can 
estimate the relative response factors of the related substances at different wavelengths. 
 
Disregard of whether Area % or External Standard approach is used, if the relative response 
factors of some significant related substances are far from unity, a response factor correction 
must be applied. The optimum wavelength of detection is the wavelength that gives the highest 
sensitivity (λmax) for the significant related substances and minimizes the difference in response 
factors between those of the active pharmaceutical ingredient and the related substances. After 
the optimum wavelength is determined, use a highly stressed sample (e.g., 5% degradation) to 
verify that the selected wavelength will give the highest % related substance results. 
 
2.5.4. Overall accuracy 
A final check of the method performance is to determine the overall accuracy of the method. 
Unlike the accuracy from sample preparation, which simply compares the response of the analyte 
with and without spiking with matrix, the overall accuracy compares the % related substances 
calculated from an accurate solution with that of the theoretical value. The accuracy solutions are 
the solutions spiked with known concentrations of related substances and matrix. Since the 
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extraction efficiency, choice of wavelength and the bias in standardization influence the 
calculated related substance result, this is the best way to investigate the accuracy of the method. 
Overall accuracy reflects the true accuracy of the method. 
 
2.6. METHOD OPTIMIZATION/ ROBUSTNESS 
After the individual components of the method are optimized, perform the final optimization of 
the method to improve the accuracy, precision and LOQ. Use an experimental design approach 
to determine the experimental factors that have significant impact on the method. This is very 
important in determining what factors need to be investigated in the robustness testing during the 
method validation. To streamLine the method optimization process, use Plackett Burmann 
Design (or similar approach) to simultaneously determine the main effects of many experimental 
factors. 
Some of the typical experimental factors that need to be investigated are: 
HPLC conditions: % organic, pH, flow rate, temperature, wavelength, column age. 
Sample preparation: % organic, pH, shaking/sonication, sample size, sample age. 
Calculation/standardization: integration, wavelength, standard concentration, response factor 
correction. 
Typical responses that need to be investigated are: 
Results: precision (%RSD), % related substance of significant related substances, total related 
substances. 
Chromatography: resolution, tailing factor, separation of all related substances. 
 
2.7. METHOD VALIDATION 
2.7.1. Robustness 
Method validation should be treated as a “final verification” of the method performance and 
should not be used as part of the method development. Some of the typical method validation 
parameters should be studied thoroughly in the previous steps. In some cases, robustness can be 
completed in the final method optimization before method validation. At this point, the 
robustness experiments should be limited only to the most significant factors (usually less than 4 
factors). In addition, unlike the final method optimization, the experimental factors should be 
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varied within a narrow range to reflect normal day to day variation. During the method 
validation, the purpose is to demonstrate that the method performance will not be significantly 
impacted by slight variations of the method conditions. 
 
2.7.2. Linearity, Accuracy, Response Factor 
Linearity, accuracy and response factors should be established for the significant related 
substances during the method validation. In order to limit the workload of method development, 
usually less than 3 significant related substances should be selected in a method. Therefore, the 
other related substances should not be included in these experiments. 
 
2.7.3. System suitability criteria 
It is advisable to run system suitability tests in these robustness experiments. During the 
robustness testing of the method validation, critical method parameters such as mobile phase 
composition and column temperature are varied to mimic the day-to-day variability. Therefore, 
the system suitability results from these robustness experiments should reflect the expected 
range. Consequently, the limits for system suitability tests can be estimated from these 
experiments. 
 
3. DEGRADATION STUDIES (20-24) 
A degradation product is defined as a chemical change in the drug molecule brought about over 
time and/or by action of, e.g., light, temperature, pH, or water, or by reaction with an excipient 
and/or the immediate container/closure system (also called decomposition product). 
 
ICH Guideline on Stability Testing 
Stress testing helps determine the intrinsic stability of the molecule by establishing degradation 
pathways in order to identify the likely degradation products and to validate the stability 
indicating power of the analytical procedures used. Stress testing is conducted to provide data on 
forced decomposition products and decomposition mechanisms. The severe conditions that may 
be encountered during distribution can be covered by stress testing. These studies should 
Dept. of Pharmaceutical Analysis                                                               Introduction 
 
K. M. C. H College of Pharmacy  Page 23 
 
establish the inherent stability characteristics of the molecule, such as the degradation pathways, 
and lead to identification of the degradation products and hence support the suitability of the 
proposed analytical procedures. The detailed nature of the studies will depend on the individual 
drug substance and type of drug product. 
 
The 1987 Food and Drug Administration (FDA) Stability Guideline defines stability-indicating 
methodology as: 
 
Quantitative analytical methods that are based on the characteristic structural, chemical or 
biological properties of each active ingredient of a drug product and that will distinguish each 
active ingredient from its degradation products so that the active ingredient content can be 
accurately measured. 
 
3.1.Drug Substance Degradation Studies: 
Purposeful degradation studies of the drug substance include appropriate solution and solid-state 
stress conditions (e.g., acid/base hydrolysis, heat, humidity, oxidation, and light exposure, in 
accordance with ICH guidelines). Guidelines from the United States Pharmacopoeia (USP), ICH, 
and FDA provide a brief outline of drug substance conditions. The ICH guidelines specifically 
state 
 
Stress testing is likely to be carried out on a single batch of material and to include the effect of 
temperatures in 10 ◦C increments above the accelerated temperature test condition (e.g., 50 ◦C, 
60 ◦C, etc.); humidity where appropriate (e.g. 75% RH or greater); oxidation and photolysis on 
the drug substance plus its susceptibility to hydrolysis across a wide range of pH values when in 
solution or suspension. 
 
3.1.1. Acid/Base Stress Testing: 
Acid/base stress testing is performed to force the degradation of a drug substance to its primary 
degradation products by exposure to acidic and basic conditions over time. Functional groups 
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likely to introduce acid/base hydrolysis are amides (lactams), esters (lactones), carbamates, 
imides, imines, alcohols (epimerization for chiral centers), and aryl amines. 
  
To initiate acid/base studies, a preliminary solubility screen of the drug substance is performed. 
Solubility of at least 1 mg/mL in 1 N acidic and basic condition is recommended for the 
acid/base stress testing; however, concentrations less than 1 mg/mL can be used if solubility is an 
issue. In some cases, a co-solvent may be necessary to achieve the target concentration. Special 
attention should be given to the drug substance structure when choosing an appropriate co-
solvent. 
 
 Table 2. Guidance on Acid/Base Experimental Setup: 
 
 
Samples:                                                             Drug substance + acid (1 N HCl) 
                                                                             Drug substance + base (1 N NaOH) 
                                                                             Drug substance “as is” 
                                                                             Acid control (1 N HCl) 
                                                                             Base control (1 N NaOH) 
 
Kinetic points: 0 – 1week 
 
 
 
3.1.2. Thermal and Thermal/Humidity Stress Testing: 
The goal of thermal and thermal/humidity studies is to force the degradation of drug substances 
over time to determine the primary thermal and/or humidity degradation products. 
 
Table 3. Guidance for Thermal Stress Length of Study: 
 
Temperature Length of storage 
 
         30˚C                                                   1 year 
         40˚C                                                   6 months 
         50˚C                                                  12 weeks 
         60˚C                                                    6 weeks 
         70˚C                                                    3 weeks 
         80˚C                                                   11 days 
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Table 4. Guidance for Thermal/Humidity Experimental Setup: 
 
 
Samples:                                                  70˚C/30% RH (ambient humidity) 
                                                                 70˚C/30% RH 
 
 
Time points:                                           0 – 6 week 
 
 
3.1.3. Oxidation: 
 
Oxidative studies are executed to force the degradation of drug substances to determine the 
primary oxidative degradation products. Oxidative degradation is a serious stability problem and 
can cause a major halt in pharmaceutical development. The 1987 Stability Guidelines state that a 
high oxygen atmosphere should be evaluated in stability studies on solutions or suspensions of 
the bulk drug substance. 
  
Table 5. Guidance for Oxidative Degradation Experimental Setup: 
 
 
Samples:                            Oxygen with initiator 
                                                                Oxygen without initiator 
                                                                Argon with initiator 
                                                                Thermal control 
                                                                Initiator and antioxidant without drug substance 
 
Time points:                                           0 – 10 days 
 
 
 
3.1.4. Photostability: 
The goal of the photostability studies is to force the degradation of drug substances via UV and 
fluorescent conditions over time to determine the primary degradation products. UV and visible 
light are the most energetic electromagnetic radiation sources to which pharmaceutical drug 
substances and drug products are typically exposed. A molecule absorbs light when an 
absorption band exists that overlaps to some extent with the incident light energy and a valence 
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electron in the relevant chromophore is raised to an excited state. Light stress conditions can also 
induce photo oxidation by free radical mechanisms.  
 
 
Table 6. Guidance for Ultraviolet Degradation Experimental Set Up: 
 
 
 
 
3.1.4.1.Ultraviolet Exposure: 
ICH guidelines specify an exposure of 200 watt h/m2 for ultraviolet light confirmatory testing 
(1× ICH). Recommended stress conditions and time points to be tested are 5× and 10× ICH for 
solid drug substances 
All samples should be taken at the appropriate kinetic time points and protected from any further 
light exposure. Light measurements should be taken in watts/m2 to be consistent with the ICH 
guidelines. 
 
3.1.4.2.Fluorescence Exposure: 
ICH guidelines specify an exposure of 1.2×106 lux hours for fluorescence (1× ICH). 
Recommended stress conditions and time points to be tested are 5× and 10× ICH for solid drug 
substances. 
Filters may be useful to determine any wavelength range causing instability. For example, a 400 
nm filter in fluorescence experiments to look at the 400–700 nm component and eliminate the 
UV portion is especially critical in solution experiments. If photodegradation is observed, one 
can determine whether it is the result of visible or ultraviolet light using appropriate spectral 
filters. 
 
 
 
 
 
Samples:             Ultraviolet 
                                                                 Thermal foil-wrapped control 
 
 
Time points:                                           5× and 10 × ICH* 
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Table 7.  Guidance for Fluorescence Degradation Experimental Set Up: 
 
 
Samples:            Fluorescence 
                                                               Thermal foil-wrapped control 
 
 
Time points:                                           5× and 10 × ICH* 
 
* Note: ICH fluorescent conditions = 1.2 × 106 lux hrs 
 
3.2.Degradation Prediction: 
Degradation prediction is extremely helpful for understanding a degradation mechanism. One 
program that has been particularly useful is CAMEO (computer assisted mechanistic evaluation 
of organic reactions). CAMEO is a computer program that predicts the products of organic 
reactions given starting materials, reagents, and conditions. The analyses cover the key 
degradation conditions, basic/nucleophilic, acidic/electrophilic, radical, oxidative/ reductive and 
photochemical, as well as mechanistic interpretations of these reactions. 
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Chapter 2 
LITERATURE REVIEW 
Shende et al.28 developed an isocratic reversed-phase high-performance liquid chromatographic 
(RP-HPLC) method for analysis of irinotecan HCl and validated. Separation was achieved on a 
C18 column with potassium dihydrogen phosphate buffer (pH adjusted to 3.5 with 
orthophosphoric acid)–acetonitrile–methanol 55:25:20 (v/v) as mobile phase at a flow rate of 1.0 
mL min−1. UV detection was performed at 254 nm. The method is simple, sensitive, rapid, and 
selective, and linear over the range 30–70 μg mL-1 for assay of irinotecan HCl. The precision of 
the assay method was below 1.0% RSD. Mean recovery was in the range 98–102%. Recovery of 
the active pharmaceutical ingredient from dosage forms ranged from 99.0 to 101.0. The method 
is useful for quality control in bulk manufacture and of the pharmaceutical formulation.  
  
Satyanarayana et al.29 have reported a reverse phase HPLC method, developed for the 
estimation of Irinotecan HCl in tablet dosage form. An X-Terra RP C18, 250 X 4.6 mm i.d, 5 m 
particle size, with mobile phase consisting of Methanol and 0.01 M Ammonium Acetate 
containing 0.1% formic acid and methanol in the ratio of 50:50 v/v was used. The flow rate was 
1 mL/min and the effluents were monitored at 250 nm. The retention time was 4.69 min. The 
detector response was linear in the concentration of 120-360 mcg/mL. The respective linear 
regression equation being Y=166582.24x+86439.5. The limit of detection and limit of 
quantification was 0.06 and 0.18 mcg/mL respectively. The percentage assay of Irinotecan HCl 
was 99.09 %. The method was validated by determining its accuracy, precision and system 
suitability. The results of the study showed that the proposed RP-HPLC method is simple, rapid, 
precise and accurate, which is useful for the routine determination of Irinotecan HCl in bulk drug 
and in its pharmaceutical dosage form. 
Venkateswara rao et al.30 developed a reverse phase high performance liquid chromatography 
(RP-HPLC) method and validated for quantitative determination of irinotecan in bulk drug 
samples and formulations. Irinotecan was analyzed by using reverse phase cyano column (4.6 
mm x 25 cm, 5 microns), with mobile phase consisting of phosphate buffer: acetonitrile (75:25 
v/v), pH adjusted to 2.5 with phosphoric acid. The flow rate was set 0.8 mL/min and the analysis 
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was performed at wavelength 225 nm using Photo Diode Array (PDA) detector at ambient 
temperature. The method was validated and stability studies were conducted under different 
conditions. The retention time for irinotecan was around 5.82 minutes. The calibration curves 
were linear (R2 ≥0.9998) over a concentration range from 20.0 to 80.0 µg/mL. Limit of detection 
(LOD) and Limit of quantitation (LOQ) were 8 ng/mL and 24 ng/mL respectively. The 
developed method was successfully applied to estimate the amount of irinotecan in injection 
formulations. 
Owens et al.31 developed a method for the determination of CPT-11 and the three metabolites 
SN-38, SN-38G, and APC in biological matrices. In most of these published methods, 
chromatography was carried out with fluorescence detection. Liquid chromatography-mass 
spectrometry methods have also been described, but despite the latter methods providing good 
results, the instrumentation involved is expensive and not always readily available for routine 
drug monitoring.          
   
Takahashi et al.32 found that both CPT-11 and SN-38 were detectable in saliva and that the 
patterns of their concentration-time curves in plasma and saliva were very similar. To date, 
however, no bioanalytical assay has been validated for the determination of irinotecan and its 
metabolites in saliva. This report describes rapid, specific, reliable, and sensitive analytical 
methods to simultaneously quantify irinotecan and four metabolites (SN-38, SN-38G, APC, and 
NPC) in human plasma and saliva. These methods, involving the use of an internal standard, 
were validated according to validation procedures, parameters, and acceptance criteria based on 
US Pharmacopoeia XXIII guidelines and Food and Drug Administration guidance.  
  
Ali mohammadi et al.33 developed a new simple high performance liquid chromatography 
(HPLC) method and validated for the simultaneous determination of irinotecan (CPT-11) and 
two related compounds viz., 7-ethyl-10-hydroxycamptothecin (SN-38) and camptothecin (CPT) 
in pharmaceutical dosage forms. Chromatography was accomplished using a reversed-phase C18 
column and ultraviolet (UV) detection and an isocratic mobile phase consisting of 3 % v/v 
triethylammonium acetate buffer (pH 3) and acetonitrile (70:30 v/v). The linear range of 
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quantitation for all the compounds was 0.1-10 μg/mL. The limit of quantitation for all the 
compounds ranged between 0.01-0.05 μg/mL. The method has the requisite accuracy, selectivity, 
sensitivity and precision to assay of CPT-11 and related compounds in pharmaceutical dosage 
forms and bulk API. 
 
Mohammed Ishaq et al.34 have reported a rapid and sensitive RP-HPLC method with UV 
detection at 222 nm for routine analysis of Irinotecan in bulk and pharmaceutical formulations. 
Chromatography was performed with mobile phase containing a mixture of acetonitrile and 
phosphate buffer in the ratio of 60:40, v/v with flow rate 1.0 mL/min. The calibration graph of 
Irinotecan was found to be linear over the range of 40 to 120 μg/mL with correlation coefficient 
of 0.9999. Sensitivity, accuracy, range, precision, robustness, ruggedness, stability, specificity, 
limit of detection, limit of quantification and system suitability parameters were validated for the 
developed method. The developed method was successfully applied to estimate the amount of 
irinotecan in injection formulations.         
  
Gogineni Ratna Prasad et al.35 developed a simple, specific, accurate and precise reverse phase 
high performance liquid chromatographic method and validated for the estimation of Irinotecan 
in tablet dosage form. An Inertsil ODS C-18, 5 μm column having 250 x 4.6 mm internal 
diameter in isocratic mode with mobile phase containing Methanol: Triethylamine: 1% 
Orthophosphoric acid in the ratio of 60:5:35 (v/v/v) was used. The flow rate was 1.0mL/min and 
effluents were monitored at 254 nm. The retention time for Irinotecan was 5.109 min. The 
method was validated for linearity, accuracy, precision, specificity, limit of detection, limit of 
quantification and robustness. Limit of detection and limit of quantification were found to be 
0.09 ppm and 0.297 ppm respectively. The proposed method was successfully applied for the 
quantitative determination of Irinotecan in tablet formulation.     
    
Saini P.K et al.36 proposed a selective and highly sensitive reverse phase ultra performance 
liquid chromatographic (UPLC) method and validated for the quantitation of the novel anticancer 
agent irinotecan hydrochloride in Bulk and its injection dosage form. The method utilizes sample 
preparation step followed by separation on a waters BEH C18, 50 × 2.1 mm, 1.7 μm particle size 
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column in gradient mode using 0.1 % v/v orthophosphoric acid in water and acetonitrile as the 
mobile phase. The analytical column was thermo stated at 50°C and flow rate was set at 0.5 mL 
per min. The eluted peaks were detected by photodiode array (PDA) detector at a wavelength of 
254 nm. The retention time of irinotecan was found 2.127 min. Linearity responses in analyte 
standard peak areas were observed over the concentration ranges of 100 - 500 μg/mL. The limit 
of detection and limit of quantification were found 0.0560 and 0.1698 μg/mL, respectively. 
Percentage recoveries were obtained in the range of 97.5 % and 98.88 %.  The proposed method 
is precise, accurate, selective and reproducible. 
Sushama Talegaonkara et al.37 developed a simple, sensitive, precise and accurate stability-
indicating high performance thin-layer chromatographic method for analysis of irinotecan both 
as bulk drug and marketed injectables and validated as per ICH guidelines. Chromatographic 
separation was achieved on LiChrospher aluminum plates precoated with silica gel 60F254 as 
stationary phase. The solvent system consisted of acetone –ethyl acetate –acetic acid 8.5:1.5:0.1 
(v/v/v) and this system were found to give compact spots for irinotecan at Rf value of 0.31 ± 
0.02. Densitometric analysis was performed in the absorbance at 366 nm. The linear regression 
analysis for the calibration plots showed good linear relationship with R2 = 0.9973 ± 0.0013 in 
the concentration range of 50–500 ng/spot. The % recovery (94.63–101.40%) and precision (≤ 
4.30) were found to be satisfactory. Irinotecan was subjected to acid and alkali hydrolysis, 
oxidation, thermal and ultraviolet radiation treatments. All the peaks of degradation products 
were well resolved from the standard drug with significantly different retention factor (Rf) 
values. Developed method effectively separated out the drug from its degradation products and 
hence can be used as stability-indicating method as well as in routine analysis of irinotecan. 
Wei Zhang et al.38 developed a sensitive and selective liquid chromatographic–tandem mass 
spectrometric (LC–MS/MS) method for the determination of Irinotecan (CPT-11) and its 
metabolites in human plasma. Samples were prepared after protein precipitation and analyzed on 
a C18 column interfaced with a Q-Trap tandem mass spectrometer. Positive electrospray 
ionization was employed as the ionization source. The mobile phase consisted of acetonitrile–
water (0.05% formic acid), using gradient procedure. The analytes and internal standard 
camptothecin were both detected by use of multiple reaction monitoring mode. The method was  
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linear in the concentration range of 10.0–2000.0 ng/mL for CPT-11 and 0.5–200.0 ng/mL for 7-
ethyl-10-hydroxycamptothecin (SN-38), respectively. The lower limit of quantification (LLOQ) 
was 10 ng/mL for CPT-11 and 0.5 ng/mL for SN-38. The intra- and inter-day relative standard 
deviation across three validation runs over the entire concentration range was less than 10.6%. 
The accuracy determined at three concentrations was within ± 11.4% in terms of relative error. 
Due to the unavailability of standard for 7-ethyl-10-O-glucuronyl-camptothecin (SN-38G) and 
the importance of knowing the concentration of this metabolite, we developed a method for 
analysis SN-38G by taking advantage of the quantitative conversion of SN-38G to SN-38 using 
glucuronidase. This enzymatic method of identification and quantitation of gluconated 
compound can be widely used when the standard for phase II glucuronide metabolites are not 
available. 
Iman Barilero et al.39 have reported A sensitive high-performance liquid chromatographic assay 
suitable for the simultaneous determination of irinotecan HCl (I)  and its active metabolite SN-38 
(II) in human plasma, and their preliminary clinical pharmacokinetics, are described. Plasma 
samples were processed using a solid-phase (C18) extraction step allowing mean recoveries of I, 
II and the internal standard camptothecin (III) of 84, 99 and 72%, respectively. The extracts were 
chromatographed on a C18 reversed-phase column with a mobile phase composed of acetonitrile, 
phosphate buffer and heptanesulphonic acid, with fluorescence detection. The calibration graphs 
were linear over a wide range of concentrations (1 ng/mL-10 µg/mL), and the lower limit of 
determination was 1 ng/mL for both I and II. The method showed good precision: the within-day 
relative standard deviation (R.S.D.) (5- l000 ng/mL) was 13.0% (range 4.9-19.4%) for I and 
12.8% (6.7- 19.1%) for II; the between-day R.S.D. (5-10 000 ng/mL was 7.9% (5.417.5%) for I 
and 9.7% (3.515.1%) for II. Using this assay, plasma pharmacokinetics of both I and II were 
simultaneously determined in three patients receiving 100 mg/m2I as a 30-min intravenous 
infusion. The mean peak plasma concentration of I at the end of the intravenous infusion was 
2400 ±285 ng/mL (mean ± standard error of the mean). Plasma decay was triphasic with half-
lives α, β and  ∞ of 5.4 f 1.8 min, 2.5 f 0.5 h and 20.2 f 4.6 h, respectively. The volume of 
distribution at steady state was 105 ± 15 l/m2, and the total body clearance was 12.5 ± 1.9 l/h m2. 
The maximum concentrations of the active metabolite II reached 36 f 11 ng/mL. 
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Chapter 3 
DRUG PROFILE (25-27) 
IRINOTECAN HYDROCHLORIDE 
Irinotecan HCl also called as Irinotecanum available in market in various following Brand names  
• Camptosar 
• CP0 
• Irinotecan 
• CPT-11 
• Irinocam 
• Torsin 
• campto 
Structure: 
              .HCl .3H2o 
Molecular formula:   
C
33
H
38
N
4
O
6 · 
HCl 3H
2
O 
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Molecular weight:   
   Trihydrate: 677.18   
Anhydrous: 623.14 
 
Chemical name:  
(S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3, 14-dioxo-1H- Pyranol-[3`, 4`:6,7]-indolizino 
[1,2-b]quinolin-9-yl-[a,4`-bipiperidine]-1`-carboxylate, monohydrochloride, trihydrate. 
Content:    
Irinotecan Hydrochloride contains NLT 98.0% and NMT 102.0% of C33H38N4O6·HCl, calculated 
on the anhydrous basis. 
Characteristics:  
 
Appearance: Pale yellow crystalline powder 
Solubility: Slightly soluble in water, methanol and ethanol, freely soluble in glacial acetic acid. 
Identification: 
IR 
Melting/Freezing Point:  222-223oC 
Boiling Point:  100°C  
 PH: 3.5 
Mechanism of action:        
 Irinotecan inhibits the action of topoisomerase I. Irinotecan prevents religation of the 
DNA strand by binding to topoisomerase I-DNA complex. The formation of this ternary 
complex interferes with the moving replication fork, which induces replication arrest and lethal  
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double-stranded breaks in DNA. As a result, DNA damage is not efficiently repaired and 
apoptosis (programmed cell death) occurs. 
Toxicity:         
 Gastrointestinal complications such as nausea, vomiting, abdominal cramping, diarrhea, 
and infection. 
Storage: 
  Stored in Glass containers, Polyethylene or polypropylene containers at 15-30oC, and 
protected from light. 
 
Category: 
• Antineoplastic Agents 
• Radiation-Sensitizing Agents 
• Parasympathomimetics 
• Enzyme Inhibitors 
• Prodrugs 
• Phytogenic agent 
• Extreme suppression of the immune system. 
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Chapter 4 
AIM AND OBJECTIVE 
SN-38 (7-ethyl-10-Hydroxycamptothecin) is one of the metabolite/related substance 
present in irinotecan HCl (40-41). The assessment of the limit of SN38 concentrations in humans is 
very important, since SN38 is 100 to 1,000 fold more cytotoxic than the parent compound. SN-
38 is reported to be associated with the severe diarrhea with one of the major side effects causing 
direct enteric injury (Araki et al., 1993). There is no report for the quantification of SN-38 in 
irinotecan HCl and on forced degradation studies of irinotecan HCl by HPLC method. 
Hence it was proposed to develop and validate a RP-HPLC method for detection and 
quantification of SN-38 in irinotecan HCl and to perform the forced degradation studies of 
irinotecan HCl in order to identify and quantify the degradents by HPLC.  
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Chapter 5 
PLAN OF WORK 
• PHASE -I 
1. Optimization of chromatographic conditions, 
 Selection of wavelength  
 Selection of initial separation conditions   
 Selection of mobile phase (pH, peak modifier, solvent strength, 
  ratio and flow rate)      
 Nature of the stationary phase 
 Selection of separation method and agent 
• PHASE-II 
            2. Validation of the method 
The developed method to be validated using the various validation   parameters 
such as,  
 Accuracy 
 Precision 
 Linearity and of detection (LOD) / Limit of quantitation (LOQ) 
 Selectivity / Specify 
 Robustness / ruggedness 
 System suitability. 
• PHASE-III 
     3. Quantification of Related substance: 
Estimation of Related substance (SN-38) in marketed Irinotecan HCl formulation 
and verification of its limits 
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• PHASE-IV 
4. Performance of forced degradation studies such as     
 Acid degradation 
 Alkaline degradation 
 Oxidative degradation 
 Photolytic degradation   
 Thermal degradation 
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Chapter 6 
EXPERIMENTAL 
6.1 Analytical Method Development and determination of Irinotecan HCl and its related 
substance 7-ethyl 10-hydroxy camptothecin (SN-38) in marketed formulation 
6.1.1 MATERIALS AND INSTRUMENTS USED 
a) Drug sample & Study products 
Irinotecan HCl was obtained from Dr. Reddy’s Laboratories, Hyderabad and 7-ethyl 10-hydroxy 
camptothecin (SN-38) was obtained from Henan Dongtai Pharm Co., Ltd, China. 
Test product:  
Irinocam-40 mg (Dr. Reddy’s Laboratories) injection was purchased from the local market. 
b) Chemicals and solvents used for estimation: 
• HPLC grade Water            
• HPLC grade Acetonitrile           
• HPLC grade Methanol            
• Analytical grade  Dihydrogen sulphoxide     
• Analytical grade Trichloro acetic acid           
• Analytical grade Distilled water            
c) Instruments used: 
• Elico pH meter LI 127. 
• Shimadzu LC-20 AT HPLC. 
• Shimadzu 1700 UV Spectrophotometer. 
• Sonica Ultrasonic cleaner.  
• Solvent filtration unit – Millipore. 
• Shimadzu electronic balance AX 200. 
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D) preparation of standard stock solutions: 
I. Irinotecan HCl (10 µg): 
Ten milligrams (mg) of standard Irinotecan HCl was dissolved in the 10 mL of methanol, 
then serial dilutions were made with water to get a final concentration of 10 µg/mL. 
 
II. SN-38 (7-ethyl 10-hydroxy camptothecin) 10 µg: 
Ten milligrams (mg) of standard SN-38 was dissolved in the 10 mL of Dihydrogen 
sulphoxide, then serial dilutions were made with methanol to get a final concentration of 
10 µg/mL.  
6.1.2 OPTIMIZATION OF CHROMATOGRAPHIC CONDITIONS FOR METHOD 
DEVELOPMENT OF IRINOTECAN HCl AND SN-38 (7-ETHYL 10-HYDROXY 
CAMPTOTHECIN) 
 Method development: 
           The aim of the present study was to develop and validate the RP-HPLC method for the 
estimation of Irinotecan HCl and SN-38 in the injection dosage form. 
Selection of wavelength 
An UV-Visible spectrum of 10 µg/mL Irinotecan HCl in methanol and SN-38 in 
Dihydrogen sulphoxide and methanol was recorded by scanning in the range of 200 nm to 800 
nm. From the UV-Visible spectrum wavelength of 372 nm was selected. At this wavelength 
Irinotecan HCl showed good absorbance.  
Selection of chromatographic method 
Proper selection of the method depends upon the nature of the sample 
(ionic/ionisable/neutral molecule), its molecular weight and solubility. The drug selected in the 
present study is polar in nature and hence a reverse phase HPLC was selected for the initial 
separations because of its simplicity and suitability. 
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Initial separation conditions 
 Standard solution:  10 μg/mL of Irinotecan HCl in HPLC grade Methanol. 
 Equipment 
System      : Shimadzu gradient HPLC 
Pump        : LC – 20AT prominence solvent delivery system 
Detector    : SPD-M20A Prominence Diode array detector 
Injector     : Rheodyne 7725i with 20 μL loop 
Chromatographic condition 1 
     Stationary phase    :  Phenomenex Luna C18 Column 
       Mobile phase       : Solvent A: 10 mM ammonium acetate in 100mL HPLC 
grade water PH adjusted to 4 with 
orthophosphoric acid                                         
                                                   Solvent B: Acetonitrile and methanol (50:50 v/v)         
          
     Solvent ratio     : 60:40 
      Detection     : 372 nm 
  Flow rate     : 1.0 mL/min 
      Sample size     : 20 μL 
       Needle wash     : water HPLC grade  
            Column temperature    : Ambient 
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The retention time of Irinotecan HCl andSN-38 were found to be 6.67 and 8.75 min but 
peak tailing was observed for Irinotecan HCl as shown in Fig. 3 &4. So we adjusted the PH of 
the buffer solution. 
 
Chromatographic condition 2 
                       Stationary phase   :  Phenomenex Luna C18 Column 
Mobile phase         : Solvent A: 10 mM ammonium acetate in 100 mL HPLC   
grade water PH adjusted to 5.0 with 
orthophosphoric acid                                         
                                             Solvent B: Acetonitrile and methanol (50:50 v/v)  
          Solvent ratio          : 60:40 
          Detection          : 372 nm 
           Flow rate          : 1.0 mL/min 
         Sample size          : 20 μL 
         Needle wash          : water HPLC grade  
        Column temperature    : Ambient 
Retention time for irinotecan HCl was found to be 8.82 and for SN-38 we found 13.3 min 
but splitting and peak tailing was observed for SN-38 as shown in Fig. 5 & 6. So we altered the 
ratio of the mobile phase system and run for SN-38. 
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Chromatographic condition 3 
                       Stationary phase      :  Phenomenex Luna C18 Column 
Mobile phase         : Solvent A: 10 mM ammonium acetate in 100 mL HPLC   
grade water PH adjusted to 4.5 with 
orthophosphoric acid                                         
                                                Solvent B: Acetonitrile and methanol (50:50 v/v)  
          Solvent ratio          : 55:45 
          Detection          : 372 nm 
           Flow rate          : 1.0 mL/min 
         Sample size          : 20 μL 
         Needle wash          : water HPLC grade  
         Column temperature    : Ambient  
   
Retention time for SN-38 was found to be 6.8 min and peak splitting was observed with 
tailing as shown in Fig. 7. Then we altered the buffer system.  
Chromatographic condition 4        
Stationary phase        :  Phenomenex Luna C18 Column 
Mobile phase        : Solvent A: 0.5% Trichloro acetic acid in 100 mL of HPLC 
grade water                                          
                                             Solvent B: methanol  
          Solvent ratio          : 55:45 
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          Detection          : 372 nm 
           Flow rate          : 1.0 mL/min 
         Sample size          : 20 μL 
         Needle wash          : water HPLC grade  
        Column temperature    : Ambient  
 Retention time for SN-38 was found to be 13.8 min but broad peak was obtained as 
shown in Fig. 8. Then we altered the organic phase. 
Chromatographic condition 5 
Stationary phase        :  Phenomenex Luna C18 Column 
Mobile phase         : Solvent A: 0.5% Trichloro acetic acid in 100 mL of HPLC 
grade water                                          
                                            Solvent B: Acetonitrile and methanol (50:50 v/v) 
          Solvent ratio          : 55:45 
          Detection          : 372 nm 
           Flow rate          : 1.0 mL/min 
         Sample size          : 20 μL 
         Needle wash          : water HPLC grade  
        Column temperature    : Ambient 
  Both Irinotecan HCl and SN-38 were merged and gave retention time at 5.8 min in 
individual chromatograms as shown in Fig. 9 & 10. 
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Chromatographic condition 6 
Stationary phase       :  Phenomenex Luna C18 Column 
Mobile phase       : Solvent A: 0.5% Trichloro acetic acid in 100 mL of HPLC 
grade water                                          
                                             Solvent B: Acetonitrile and methanol (50:50 v/v) 
          Solvent ratio          : 60:40 
          Detection          : 372 nm 
           Flow rate          : 1.0 mL/min 
         Sample size          : 20 μL 
         Needle wash          : water HPLC grade  
        Column temperature    : Ambient  
 Retention time for Irinotecan HCl and SN-38 were found to be 8.53 and 7.25 min 
with good resolved peaks as shown in Fig. 11 & 12. 
Chromatographic condition 6 for mixture: 
Stationary phase       :  Phenomenex Luna C18 Column 
Mobile phase       : Solvent A: 0.5% Trichloro acetic acid in 100 mL of HPLC 
grade water                                          
                                             Solvent B: Acetonitrile and methanol (50:50 v/v) 
          Solvent ratio         : 60:40 
          Detection         : 372 nm 
           Flow rate         : 1.0 mL/min 
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         Sample size         : 20 μL (mixture of both) 
         Needle wash         : water HPLC grade  
        Column temperature   : Ambient 
 Retention time for Irinotecan HCl and SN-38 were found to be 8.53 and 7.25 min 
with good resolved peaks in chromatogram without merging as shown in Fig. 13. 
Effect of ratio of mobile phase 
 Aqueous and organic mixture with 60:40 and 55:45 ratios were used as the mobile phase. 
At 60:40 ratio, the symmetric peaks were eluted at 8.63 and 7.35 min. At 55:45 ratio the peaks 
were asymmetric. Thus for the present study 60:40 ratio mobile phase system was selected. 
Finally, the following Fixed Chromatographic Conditions were selected for the estimation of 
Irinotecan HCl and its related substance (SN-38) in marketed formulation. 
Stationary phase       :  Phenomenex Luna C18 Column 
Mobile phase        : Solvent A: 0.5% Trichloro acetic acid in 100 mL of HPLC 
grade water                                          
                                             Solvent B: Acetonitrile and methanol (50:50 v/v) 
          Solvent ratio         : 60:40 
          Detection         : 372 nm 
           Flow rate         : 1.0 mL/min 
         Sample size         : 20 μL 
         Needle wash         : water HPLC grade  
        Column temperature   : Ambient  
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6.1.3 ESTIMATION OF IRINOTECAN HCL AND ITS RELATED SUBSTANCE (SN-38) 
IN MARKETED FORMULATION: 
Preparation of standard solutions: 
I. Irinotecan HCl (10 µg): 
Ten milligrams (mg) of standard Irinotecan HCl was dissolved in the 10 mL of methanol, 
then serial dilutions were made with water to get a final concentration of 10 µg.  
II. SN-38 (7-ethyl 10-hydroxy camptothecin) 10 µg:         
Ten milligrams (mg) of standard SN-38 was dissolved in the 10 mL of Dihydrogen 
sulphoxide, then serial dilutions were made with methanol to get a final concentration of 
10 µg. 
Preparation of test (marketed formulation) solution: 
One milliliter (mL) of formulation (20 mg) was diluted to 10 mL of methanol and then serial 
dilutions were made with methanol to get final concentrations of 60 and 120 µg. 
Recording of chromatogram: 
With the optimized chromatographic conditions mentioned above, a steady baseline for about 20 
min was recorded. After the stabilization of the baseline, the standard solution were injected and 
chromatograms were recorded until the reproducibility of the peak areas were found satisfactory 
and finally 10 μg/mL of the standard solution of the individual samples of Irinotecan HCl and 
SN-38 and Standard solutions containing 1-5 µg /mL of Irinotecan HCl and SN-38 were injected 
and chromatograms were recorded. Retention time of Irinotecan HCl and SN-38 were found to 
be at 8.6 and 7.3 min respectively and the chromatograms are shown in Fig. 14, 15, 16, 17, 18, 
19.  
The procedure was repeated for sample (formulation) solution and the chromatogram is 
recorded as shown in Fig. 20, 21, 22, 23. Peak areas of the sample chromatograms were recorded 
and the amount of Irinotecan HCl and SN-38 were calculated from regression equation. 
 
Dept. of Pharmaceutical Analysis                                               Experimental  
 
K. M. C. H College of Pharmacy  Page 54 
 
6.1.4 VALIDATION OF THE HPLC METHOD   
Validation is a process of establishing documented evidence, which provides a high 
degree of assurance that a specific activity will consistently produce a desired result or product 
meeting its predetermined specifications and quality characteristics. 
Significance of Method Validation: 
 The quality of analytical data is a key factor in the success of a drug development 
program. The process of method development and validation has a direct impact on the quality 
of these data. 
Analytical validation is a very important feature of any package of information submitted 
to international regulatory agencies in support of new product marketing or clinical trials 
applications. A thorough method development can almost rule out all potential problems, at the 
same time, a thorough validation programmed can address the most common ones and provide 
assurance to the intended purpose (can be used with 100% confidence). In other words, a 
thorough validation can fulfill all the technical and regulatory objectives. A direct consequence 
and most significant out come from any method validation exercise is the development of 
meaningful specifications can be predicted upon the use of validated analytical procedures that 
can assess changes in a drug substance or drug product during its life time. 
Analytical characteristics listed below may not be applicable to every test procedure or 
every particular material. It will mostly depend on the purpose for which the procedure is 
required, however, these following aspects of validation should be given due importance. 
a) Accuracy: 
Accuracy of the method was determined by recovery experiments. The reference 
standards of the respective drug were added to the sample solution at the level of 50%, 100% and 
150%. These were further diluted by procedure as followed in the estimation of formulation. The 
concentrations of the drugs present in the resulting sample solution were determined by using 
validated assay method.   
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b) Precision: 
 Repeatability studies were done by consequently injecting the standard solution of same 
concentration i.e., 120 µg/mL of Irinotecan HCl. These solutions were prepared in duplicate and 
injected as per assay procedure.  
 c) Linearity and Range: 
 The calibration curve was plotted using peak area ratio Vs concentration of the standard 
solution. From the calibration curve, the slope and intercept were calculated using linear 
regression equation.  
d) Limit of Detection (LOD) and Limit of Quantification (LOQ): 
         The LOD and LOQ were separately determined, based on the calibration curve of standard 
solution. The residual standard deviation of the regression line or the standard deviation of y – 
intercepts of regression lines may be used to calculate LOD and LOQ. LOD = 3.3 × D/S and 
LOQ = 10 × D/S, where, D is the standard deviation of y – intercepts of regression line and S is 
the slope of the calibration curve. 
e) Specificity 
The specificity of the RP-HPLC method was determined by complete separation of Irinotecan 
HCl with parameters like retention time (Rt), resolution (Rs) and tailing factor (T). Tailing factor 
for peaks of Irinotecan HCL was less than 2% and resolution was satisfactory. The average 
retention time ± standard deviation for Irinotecan HCL was found to be 8.7 ± 0.468 respectively 
for six replicates. The peaks obtained for Irinotecan HCL was sharp and have clear baseline 
separation.  
f) System Suitability Studies: 
The system suitability studies were carried out as specified in USP. These parameters 
include column efficiency, resolution and capacity factor.  
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h) Robustness: 
            In order to demonstrate the robustness of the method, the following optimized conditions 
were slightly varied. 
           1)  ± 2% in ratio of acetonitrile in mobile phase, 
           2)  ± 0.1 mL of flow rate, 
           3) ± 0.2 units in the pH of buffer. 
            The separation factor, retention times and peak symmetry were then calculated. 
The deviation among the results obtained is well within the limits. Hence the method is rubusted. 
6.1.5 FORCED DEGRADATION OR STABILITY INDICATING STUDIES:  
 
The specificity of the method was demonstrated through forced degradation studies conducted on 
the sample using Acid, alkaline, oxidative, reductive and Photolytic degradations. The sample 
was exposed to these conditions and the main peak was studied for the peak purity (Irinotecan 
peak), thus indicating that the method effectively separated the degradation products from the 
Irinotecan active ingredient. 
Acid Degradation:  
About 10 mL of the 20 µg/mL of Irinotecan HCl solution (pure) and test solution was transferred 
to a 50 mL volumetric flask individually. About 10 mL of 1N hydrochloric acid was added. The 
volumetric flask was placed on a water bath maintained at 60°C for 8 h and cooled then this 
solution was neutralized with 1 mL of sodium hydroxide solution. 
Alkaline Degradation: 
 About 10 mL of the 20 µg/mL of Irinotecan HCl solution (pure) and test solution was 
transferred to a 50 mL volumetric flask individually. Ten milliliter (mL) of 1N sodium hydroxide 
solution was added. The volumetric flask was then placed on a water bath maintained at 60°C for 
8 h. Then it was cooled and neutralized with 1 mL of hydrochloric acid. 
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Oxidative Degradation:  
About 10 mL of the 20 µg/mL of Irinotecan HCl solution (pure) and test solution was transferred 
to a 50 mL volumetric flask individually .10 mL of 3% hydrogen peroxide was added. The 
volumetric flask was placed on a water bath maintained at 60°C for 8 h then cooled to room 
temperature. 
Photolytic Degradation: 
 About 50 mL of the 20 µg/mL of Irinotecan HCl solution (pure) and test solution was 
transferred to a 50 mL volumetric flask individually. Then the solutions were exposed to sun 
light for 24 h 
Thermal (or) Dry heat degradation: 
 About 100 mg of the irinotecan pure drug sample was taken in Petri dish and kept in a hot air 
oven at 60°C for 8 h to study the heat degradation. A solution of 20 µg/mL of the dry heat 
degraded sample was prepared. 
In all the forced degradation studies, a volume of 5 mL of each of the solutions from the 
degradation experiments, were transferred to 10 mL individual volumetric flasks and equal 
volumes of all the above solutions (20 μL) were injected into the column and the chromatograms 
were recorded and the chromatograms was shown in Fig. 24, 25, 26, 27, 28, 29, 30, 31, 32.  
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CHROMATOGRAMS AND PEAKS: 
 
Fig. 3 – Optimization condition 1 for Irinotecan HCl (10 µg/mL) 
 
Fig.4‐ 
Optimization condition 1 for SN‐38 (10 µg/mL) 
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Fig. 5 – Optimization condition 2 for Irinotecan HCl (10 µg/mL) 
 
 
 
Fig. 6 – Optimization condition 2 for SN‐38 (10 µg/mL) 
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Fig. 7 – Optimization condition 3 for SN‐38 (10 µg/mL) 
 
 
 
Fig. 8 ‐ Optimization condition 4 for SN‐38 (10 µg/mL) 
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Fig. 9 – Optimization condition 5 for Irinotecan HCl (10 µg/mL) 
 
 
 
Fig. 10 – Optimization condition 5 for SN‐38 (10 µg/mL) 
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Fig. 11 – Optimization condition 6 for Irinotecan HCl (10 µg/mL) 
 
 
 
Fig. 12 – Optimization condition 6 for SN‐38 (10 µg/mL) 
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Fig. 13 – Optimization condition 6, mixture of both standards (10 µg/mL) 
 
 
 
Fig. 14 – HPLC Chromatogram of Standard Irinotecan HCl (10 µg/mL) 
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Fig. 15 – UV‐spectrum for standard Irinotecan HCl (10 µg/mL) 
 
 
Fig. 16 – Peak profile for standard Irinotecan HCl (10 µg/mL) 
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Fig. 17 – HPLC chromatogram for standard SN‐38 (10 µg/mL) 
 
 
 
 
Fig. 18 – UV‐spectrum for SN‐38 (10 µg/mL) 
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Fig. 19 – Peak profile for Standard SN‐38 (10 µg/mL) 
 
 
 
 
 
 
Fig. 20 – HPLC chromatogram for marketed formulation (60 µg/mL)  
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Fig. 21 – UV‐spectrum for formulation (60 µg/mL) 
 
 
 
 
Fig. 22 ‐ HPLC chromatogram for marketed formulation (120 µg/mL)  
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Fig. 23 – UV spectrum for Formulation (120 µg/mL)  
 
 
 
 
Fig. 24 ‐ HPLC chromatogram of alkaline degradation for standard Irinotecan HCl (20 µg/mL) 
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Fig. 25 ‐ HPLC chromatogram of alkaline degradation for test Irinotecan HCl (20 µg/mL) 
 
 
 
Fig. 26 ‐ HPLC chromatogram of Oxidative degradation for standard Irinotecan HCl (20 µg/mL) 
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Fig. 27 ‐ HPLC chromatogram of Oxidative degradation for test Irinotecan HCl (20 µg/mL) 
 
 
 
Fig. 28 ‐ HPLC chromatogram of Acid degradation for standard Irinotecan HCl (20 µg/mL) 
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Fig. 29 ‐ HPLC chromatogram of Acid degradation for test Irinotecan HCl (20 µg/mL) 
 
 
Fig. 30 ‐ HPLC chromatogram of Photolytic degradation for standard Irinotecan HCl (20 µg/mL) 
 
0.0 2.5 5.0 7.5 10.0 min
0
5
10
15
20
25
mAU
/3
.2
35
/3
.8
82
/4
.2
20
/4
.6
27
/5
.0
43
/5
.7
35
/6
.5
42
/6
.9
94
S
N
-3
8/
7.
28
5
/7
.8
69
/8
.2
44
Iri
no
te
ca
n/
8.
63
6
/9
.4
02
/1
0.
43
2
0.0 2.5 5.0 7.5 10.0 min
-2
-1
0
1
2
3
4
5
6
7
8
9
mAU
/3
.3
04
/4
.0
74 /5
.7
17 /6
.2
81
/7
.8
10
/9
.7
67
Dept. of Pharmaceutical Analysis                                               Experimental  
 
K. M. C. H College of Pharmacy  Page 72 
 
 
Fig. 31 ‐ HPLC chromatogram of Photolytic degradation for test Irinotecan HCl (20 µg/mL) 
 
 
 
Fig. 32 - HPLC chromatogram of Thermal degradation for standard Irinotecan HCl (20 µg/mL) 
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Chapter 7 
 RESULTS AND DISCUSSION 
HPLC METHOD             
A RP-HPLC method was developed and validated for the estimation of Irinotecan HCl 
and its related substance in injection dosage form by using Phenomenex Luna C18 column, 5µ, 
250 × 4.60 mm, as a stationary phase and 0.5% trichloro acetic acid: Acetonitrile: Methanol (60: 
20: 20 v/v/v) as mobile phase. The flow rate was 1mL/min and the effluents were monitored at 
372 nm. The retention time (Rt) for Irinotecan HCl and SN-38 was found to be 8.65 and 7.30. 
The percentage of drug in formulation, mean and relative standard deviation were 
calculated and presented in Table 8 and the percentage of related substance (SN-38) present in 
the formulation was also calculated and presented in Table 9. The result of analysis showed that 
the amount of drug present in the formulation is in good correlation with the label claim of the 
formulation.  
VALIDATION OF THE METHOD (42-44) 
The accuracy of the method was determined by recovery experiments. A known quantity 
of the pure drug was added to the pre-analyzed sample formulations at 50%, 100% and 150% 
levels.  The recovery studies were carried out 6 times of each level and the percentage recovery 
and percentage relative standard deviation were calculated and given in Table 10.  
Table 8. Analysis of Formulation for Irinotecan HCl  
 
    
    Drug 
 
      Label     
      Claim 
 (mg/mL) 
 
     Estimated   
      Amount              
   (mg/mL) 
 
 
% Label Claim 
 
 
      %RSD*             
Irinotecan 20 mg  20.10 mg  100.5%  0.45 
*- each value is the mean of six observations 
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 Table 9. Estimation of related substance (SN-38) in Irinotecan HCl formulation 
Related 
substance 
Estimated amount (mg/mL) % Amount present 
SN-38 0.0389 mg 0.19% 
 
The percentage recovery of Irinotecan HCl was found to be in the range of 98% and 
102% and percentage of related substance (SN-38) was found to be within the limit of 0.2% .The 
recoveries of standard drugs were found to be accurate and within the specified limits. 
1. Accuracy, precision and recovery: 
Table 10: Accuracy (Recovery studies)  
 
Drug 
Label 
Claim   
mg/mL 
 
Spike 
Level (%) 
Amount    
of drug 
added 
(mg) 
Amount 
of drug 
recovered 
(mg) 
Mean 
Peak 
area 
 
Percentage
Recovery ± 
SD 
 
%RSD* 
Irinotecan 20 mg 
50  50  49.27  330386  98.54 ± 0.45 
 
 
 
0.45 
 
 
100  100  99.10  670722  99.10 ± 0.40 
 
 
0.40 
 
 
150  150  148.93  998654  99.28 ± 0.35 
 
0.36 
 
 
*-Each value is the mean of six observations.  
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Acceptance Criteria (42-44) 
                   For an assay method, mean recovery should be 100% ± 2% at each concentration over 
the range of 50-150% of the target concentration. 
From the data obtained, it was observed that the recoveries of standard drugs were found 
to be accurate and within the specified limits. 
Precision:  
The precision of the method was determined by studying repeatability and 
reproducibility. The area of drug peaks and percentage relative standard deviation of intraday 
and inter day were calculated and presented in Table 11(a) and 11(b). The results revealed that 
the developed method was found to be reproducible in nature. 
Table 11(a). Intraday Studies 
No of Injection 
Conc. of Irinotecan 
(µg/mL) 
 
Peak Area 
 
%RSD* 
6 60 
330193 
332491 
334384 
330569 
331726 
332549 
0.45 
 
 
 
*-Each value is the mean of six observations.  
Acceptance criteria (42-44) 
            The % relative standard deviation of peak areas of Irinotecan HCl should not be more 
than 2.0 
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From the data obtained, it was observed that the % standard deviation was found to be 
0.45 and the value was within the specified limits. 
Table 11(b). Inter day studies: 
Day 
Conc. of Irinotecan 
(µg/mL) 
 
Peak Area 
% RSD* 
Day 1 
 
 
 
 
120 
 
 
 
522253 
524775 
526365 
522786 
524543 
525465 
 
0.29 
 
 
Day 2 
 
 
 
120 
 
 
 
523153 
525675 
527765 
522786 
525543 
525465 
 
0.35 
 
 
Day 3 
 
 
 
120 
 
 
 
522153 
525775 
527865 
522786 
525543 
525465 
 
 
0.40 
 
 
*-Each value is the mean of six observations.  
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Acceptance criteria (42-44) 
The % relative standard deviation of peak areas of Irinotecan HCl should not be more 
than 2. Since the values obtained are less than 2%. The acceptance criterion is fulfilled. 
 
2. Repeatability: 
Table 12. Repeatability: 
Conc. of Irinotecan 
(μg/mL) 
Peak Area  % RSD* 
 
 
           
          120 
522153 
525775 
527865 
522786 
525543 
525465 
 
 
 
                  0.40 
*-Each value is the mean of six observations.  
 % RSD value for repeatability was found to be (0.40) within the limit of ICH guidelines. Since 
the method was highly precise.  
3. Linearity: 
   Irinotecan HCl and SN-38 were found to be linear in the range of 30 to 150 µg/mL 
respectively.  
The correlation coefficient of Irinotecan HCl and SN-38 were found to be 0.999 and 1.0 
respectively. The linearity range of Irinotecan HCl and SN-38S were shown in Table 13 and 14 
respectively. The calibration curves were plotted before peak area and concentration of the 
standard solutions (Fig: 33 and 34).  
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Acceptance Criteria (42-44) 
Coefficient of correlation should be not less than 0.999; the results of linearity were 
found to be within the specified  limits. 
 
4. Ruggedness:                                     
Table 15. Ruggedness studies 
Drug name 
Concentration
(µg/mL) 
Mean peak area  %RSD* 
Day‐1 analyst‐1 
Irinotecan HCl 
60 332549 
 
0.450 
 
Day‐2 analyst‐2 
Irinotecan HCl 
60 332495 
 
0.443 
 
*-Each value is the mean of six observations.  
The sample was analyzed by two different analyst with same instrument on different days 
and the results of the analysts were found to be within the limits. Thus the method is rugged.  
5. Limit of Detection and Limit of Quantification: 
The LOD is the smallest concentration of the analyte that gives a measurable response 
(signal to noise ratio of 3.3). LOD of Irinotecan HCl was found to be 0.014 µg/mL. The LOQ is 
the smallest concentration of the analyte, which gives response that can be accurately quantified 
(signal to noise ratio of 10). The LOQ of Irinotecan HCl was found to be 0.045 µg/mL. 
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6. Robustness: 
The Robustness studies were performed for the standard solutions and were presented in 
Table 16. The assay values were within the limits that the developed method is robust. 
 
Table 16.  Robustness Studies: 
Chromatographic 
Condition 
Retention Time(Rt) % Assay
Irinotecan HCl  Irinotecan HCl 
Wavelength at 372 8.68 ± 0.05 100.5% 
Wavelength at 375 8.59 ± 0.05 97.82% 
Column C18 (Nucleosil) 7.32 ± 0.07 98.27% 
Column C18 (Phenomenex) 8.68 ± 0.05 99.12% 
Flow rate 1.0 mL/min 8.65 ± 0.06 98.89% 
Flow rate 1.2 mL/min 6.67 ± 0.06 95.58% 
 
6. System Suitability: 
The system suitability studies were performed for the standard solutions and were 
presented in Table 17. The values obtained demonstrated the suitability of the system for the 
analysis of the above drug combination. 
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Table 17.  System suitability studies: 
Validation Parameters  Irinotecan HCl 
 
 Linearity range (µg/mL) 
 
 Correlation co-efficient (R2) 
   
 LOD (µg/mL) 
  
 LOQ (µg/mL) 
 
 Intraday (%RSD)* 
 
 Interday (%RSD)* 
 
 Repeatability (%RSD)* 
 
 Accuracy (%) 
 
 Peak purity index 
 
 Resolution factor (Rs) 
 
 No. of theoretical plates (N) 
 
 Capacity factor (K’) 
 
 High equivalent to theoretical plates 
(HETP) 
 
 Tailing factor  
 
   
 
30-150 
 
0.999 
 
0.014 
 
0.045 
 
0.45 
 
0.34 
 
0.40 
 
98.23-100.50 
 
1.0000 
 
3.2 
 
8439.4 
 
2.125 
 
17.60 
 
                                      
                              0.91 
 *-Each value is the mean of six observations. 
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DEGRADATION STUDIES: 
Table 18. Forced degradation studies 
Type of degradation 
Standard (pure)  Formulation (Test) 
% drug 
remained 
% 
degradn 
to R.S 
% 
degradn
Unknown 
% drug 
remained 
% 
degradn 
to R.S 
% 
degradn
Unknown
Acid degradation 
 
41.81% 
 
1.35% 
 
56.83% 
 
45.71% 
 
NIL 
 
54.28% 
 
 
Alkaline degradation 
 
 
1.29% 
 
 
76.98% 
 
 
21.73% 
 
NIL 
 
 
77.22% 
 
 
 
22.78% 
 
 
Oxidative degradation 
 
2.63% 
 
 
3.77% 
 
 
93.6% 
 
 
1.51% 
 
 
NIL 
 
 
98.49% 
 
Photolytic degradation 
 
 
NIL 
 
 
NIL 
 
 
100% 
 
 
NIL 
 
 
NIL 
 
 
100% 
 
 
Thermal degradation 
 
NIL 
 
NIL 
 
100% 
 
*** 
 
*** 
 
*** 
 
OBSERVATION: 
1. Acid degradation:  
Standard: 41.81% drug was remained without degradation, 1.35% drug was degraded as      
related substance and 56.83% drug was degraded to unknown products. 
      Test         : 45.71% drug was remained without degradation and 54.28% drug was degraded   
to unknown products. 
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2. Alkaline degradation: 
Standard: 1.29% drug was remained without degradation, 76.98% drug was degraded to related 
substance and 21.73% drug was degraded to unknown products. 
Test         : 77.22% drug was degraded to related substance and 22.78% drug was degraded to 
unknown products. Here we observed complete degradation. 
3. Oxidative degradation: 
Standard: 2.63% drug was retained without degradation, 3.77% drug was degraded to related 
substance and 93.6% drug was degraded to unknown products. 
  Test         : 1.51% drug was retained without degradation and 98.49% drug was degraded to 
unknown products. 
Photolytic degradation: 
Standard: Complete degradation to unknown products. 
Test         : Complete degradation to unknown products. 
1. Thermal degradation: 
Standard: Complete degradation to unknown products. 
INFERENCE: 
# In Acid degradation, there was 40 – 45 % unchanged Irinotecan HCl. 
# In Alkaline degradation, maximum degradation was done by converting to related 
substance. 
# In Oxidative, Photolytic and Thermal degradation, there was an almost complete 
degradation to unknown products.  
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Chapter 8 
SUMMARY AND CONCLUSION 
SUMMARY: 
# A RP-HPLC method was developed to detect and quantify the related substance (SN-38) 
in marketed Irinotecan HCl formulation, where retention times of both were found to be 
8.6 and 7.3 min respectively. 
# The proposed method was validated for linearity, range, specificity, accuracy, precision, 
LOD, LOQ and robustness as per ICH guidelines. 
# The percentage of related substance (SN-38) in the formulation was found to be within 
the limits (0.2% max). 
# The forced degradation studies are also found to be satisfactory. 
 
CONCLUSION: 
It was concluded that the developed RP-HPLC method was found to be very simple, 
reliable and selective for providing satisfactory accuracy and precision. The methods are suitable 
for routine quantitative analysis in pharmaceutical dosage forms. A stability indicating assay has 
been established by following the recommendations of ICH guidelines. 
Since the Quantification of related substance (impurity profile) in Qualitative analysis 
plays a major role in the health benefits, this study will be useful for Quality control of Irinotecan 
HCl in Pharmaceutical industries.   
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Chapter 10 
GLOSSARY 
1. Degassing: The process of removing dissolved gas from the liquid mobile phase before 
or during use. Degassing is done by heating, by vacuum, or by helium purging. 
2. Drift: The change in the baseline value over time, expressed line mathematically as the 
slope of the least line squares line fitted to the base line in a specified region 
chromatogram. 
3. Eluent:  Mobile phase used to perform a chromatographic separation. The liquid that 
exists through a chromatographic column during a separation. 
4. Equilibration: The process of bringing a chromatographic solvent (solvent, column and 
interactive surfaces) to a thermally and chemically stable, usually indicated by a drift_ 
free base line. 
5. External standard: A separate sample that contains known quantities of the same 
compounds that are in unknown sample. External standards are used for quantitation by 
matching the detector response of a component peak to a point on a calibration curve for 
that component. The calibration curve is generated from a separately processed standard 
(or a set of standards). 
6. Fronting peak: An asymmetrically shaped chromatographic peak in which the front part 
of the peak (before the apex) contains more area than the rear of the peak. The 
asymmetry factor for fronting peak has valve less than one. The opposite of fronting peak 
is a tailing peak. 
7. Gradient elution: Also called as solvent programming, a technique for decreasing the 
separation time by increasing the mobile phase strength over time during a 
chromatographic separation. Gradients can be continuous or stepwise. Binary (2- 
solvent), ternary (3-solvent) and quaternary (4- solvent) gradients are used routinely in 
HPLC. 
8. Integration: The mathematically process of calculating an area such as a 
chromatographic peak that is bounded in a part or in a whole by a curved line. 
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9. Isocratic: The condition in which the solvent composition, flow rate and the temperature 
are constant during a chromatographic run, the condition in which the solvent 
composition is constant during a chromatographic run. 
10. Linearity: The condition in which detector response is directly proportional to the 
concentration or amount of a component over a specified range of component 
concentration or amounts. A calibration curve is a straight line when the standard 
concentration is within the linear response range of the detector. The chromatography, 
accurate quantitation requires linearity of the detector response over the range of actual 
sample concentration or amounts. 
11. Mobile phase: The fluid (gas or liquid) that carries solutes through a chromatographic 
column. In LC the liquid that is pumped through the fluid path of the chromatographic 
system and into which the samples are injected. 
12. Plate count: A measure of the observed chromatographic resolution based on its 
equivalency to the number of the theoretical plates that would provide the same 
resolution.  
13. Resolution: The extent to which a chromatographic column separates components from 
each other. Mathematically defined, resolution is the difference between the peak 
retention time of a selected peak and the peak preceding it’s multiplied by a constant of 
1.178, and then divided by the sum of the peak widths at 50% of peak height. It is used to 
monitor the separation of eluting components and to establish system efficiency. 
14. Retention time: The time that elapses between the injection of a sample and the 
appearance of the peak maximum of a component in a sample. 
15. Rt ratio: The retention time of a component divided by the retention time of its reference 
peak. 
16. System suitability:  An application that applies a set of standard criteria to test if an 
entire chromatographic system and the methodology are working within acceptable 
limits. Empower software bases the system suitability testes on standard laboratory 
calculations, including United States pharmacopoeia (USP) guidelines and calculations. 
Empower software procedures reports showing statistical accuracy and reproducibility of 
the chromatographic system data. 
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17. Tailing factor: A measure of peak symmetry where a symmetrical peak has a tailing 
factor of 1. As tailing increases peak symmetry increases for system suitability the tailing 
factor is the width of the peak at 5% height divided by two times the distance from the 
peak maximum to the leading edge of the peak (where the distance is measured at point 
5% of the peak height from the baseline). 
18. Capacity factor: A chromatographic parameter that measures retention time of a sample 
molecule relative to the column dead volume. 
19. Acceptance criteria: Numerical limits ranges or other suitable for acceptance of the 
results of analytical procedures. 
20. Detection limit: The detection limit of an individual analytical procedure is the lowest 
amount of analyte in a sample that can be detected but not necessarily quantitated as an 
exact value. 
21. Drug product: A finished dosage form, for example a capable tablet or solution that 
contains a drug substance, but not necessarily in association with one or more other 
ingredients. 
22. Drug substance: Active ingredient: an active ingredient that is intended to furnish 
pharmacological activity or other direct effect the structure or any function of the human 
body. The active ingredient does not include intermediates used in the synthesis of such 
ingredient. The term includes those components that may undergo chemical change in the 
manufacture of the drug product and be present in the drug product in a modified form 
intended to furnish the specified activity or effect.  
23. Reagent: For analytical procedures any substance used in a reaction for the purpose of 
detecting measuring examining or analyzing other substance. 
24. Specification: The quality standards (i.e.., tests, analytical procedures, and acceptance 
criteria) provided in an approved application to confirm the quality of the drug 
substances, drug products, intermediates, raw materials, reagents, and other components 
including container closure systems, and in-process materials. 
25. Spiking: The addition of small known amount of a known compound to a standard, 
sample, or placebo, typically for the purpose of confirming the performance of an 
analytical procedure of an analytical procedure or the calibration of an instrument. 
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26. Working standards: A standard that is qualified against and used instead of the 
reference standard (also known as in-house or secondary standards). 
27. Response factor: the response of drug substance or related substances per unit weight. 
Response factor=response (in response units)/concentration (in mg/mL) 
28. Relative response factor: the ratio of the response factor of individual related substance 
to that of a drug substance to correct for differences in the response of related substances 
and that of the drug substance. 
Relative response factor = response factor of individual related substance/response   
factor of drug substance. 
 
